10mM in DMSO for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 2 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Information
Zaltoprofen is an inhibitor ofCOX-1andCOX-2for treatment of arthritis.
In vitro
Zaltoprofen binds to specific sites on the protein of the bradykinin B2 receptor, hence we have examined the effect of zaltoprofen on bradykinin-induced responses of adult DRG neurons to investigate possible interaction sites. Zaltoprofen most potently inhibits bradykinin-enhancement of capsaicin-induced Ca2+ uptake into DRG neurons. Zaltoprofen also significantly inhibits bradykinin-induced 12-lipoxygenase (12-LOX) activity and the slow bradykinin-induced onset of substance P release from DRG neurons. Zaltoprofen produces an analgesic action on bradykinin-induced nociceptive responses by blocking the B(2) receptor-mediated pathway in the primary sensory neurons. Zaltoprofen completely inhibits the bradykinin-induced increase of [Ca(2+)](i), which is inhibited by B(2) antagonist D-Arg-[Hyp(3), Thi(5,8), D-Phe(7)]-bradykinin, but not by B(1) antagonist. Zaltoprofen at 1nmol shows strong analgesic action on BK (i.pl.)-induced nociceptive flexor responses, whereas loxoprofen or its active metabolite loxoprofen-SRS does not. Zaltoprofen also inhibits the nociception induced by [Tyr8]-BK, a specific agonist of B2-type BK receptor, but does not affect the nociception by [Lys-des-Arg9]-BK, a specific agonist of B1-type BK receptor. Zaltoprofen is a non-steroidal anti-inflammatory drug (NSAID) causes potent inhibition of cyclooxygenase-2 with fewer side effects on the gastrointestinal tract.
In vivo
Zaltoprofen improves the loss in body weight in both Con A-treated mice and carbon tetrachloride-treated rats. Zaltoprofen (10 mg/kg) administrated at 8 h after Con A treatment is found to inhibit the Con A-induced reduction in body weight. Zaltoprofen (10 mg/kg) combined with Con A results in four times greater food intake than that in mice treated with only Con A.
Cell Data
cell lines：
Concentrations：
Incubation Time：
Powder Purity:≥99%
| Isomeri SMILES | CC(C1=CC2=C(C=C1)SC3=CC=CC=C3C(=O)C2)C(=O)O |
|---|---|
| RTECS | HQ2526700 |
| CAS alternativo | 74711-43-6 |
| PubChem CID | 5720 |
| Peso molecolare | 298.36 |
| Reaxy-Rn | 6770548 |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Solubilità | Solubility (25°C) In vitro DMSO: 0.01 mg/mL (0.04 mM); Water: Insoluble; Ethanol: Insoluble; |
|---|---|
| Punto di fusione (°C) | 137 °C |
| 1. Qi Tian, Peng Quan, Liang Fang, Hui Xu, Chao Liu. (2021) A molecular mechanism investigation of the transdermal/topical absorption classification system on the basis of drug skin permeation and skin retention. INTERNATIONAL JOURNAL OF PHARMACEUTICS, [PMID:34506925] [10.1016/j.ijpharm.2021.121082] |
| 2. Luo Zhi-yuan, Li Zhi-yong, Liu Hai-yan, Tang Min-qiong, Shi Zhi-guo. (2015) Click chemistry-based synthesis of water-dispersible hydrophobic magnetic nanoparticles for use in solid phase extraction of non-steroidal anti-inflammatory drugs. MICROCHIMICA ACTA, 182 (15): (2585-2591). [PMID:] [10.1007/s00604-015-1638-x] |
